Skip Navigation


Human Molecular Genetics Advance Access originally published online on August 19, 2009
Human Molecular Genetics 2009 18(23):4467-4477; doi:10.1093/hmg/ddp399
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/23/4467    most recent
ddp399v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Vishnudas, V. K.
Right arrow Articles by Miller, J. B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vishnudas, V. K.
Right arrow Articles by Miller, J. B.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Ku70 regulates Bax-mediated pathogenesis in laminin-{alpha}2-deficient human muscle cells and mouse models of congenital muscular dystrophy

Vivek K. Vishnudas1,2 and Jeffrey Boone Miller1,2,3,*

1 Neuromuscular Biology & Disease Group and 2 Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, Boston Biomedical Research Institute, 64 Grove Street, Watertown, MA 02478, USA and 3 Department of Neurology, Harvard Medical School, Boston, MA 02115, USA

* To whom correspondence should be addressed. Tel: +1 6176587737; Fax: +1 6179721761; Email: miller{at}bbri.org

Received July 17, 2009; Accepted August 17, 2009

The severely debilitating disease Congenital Muscular Dystrophy Type 1A (MDC1A) is caused by mutations in the gene encoding laminin-{alpha}2. Bax-mediated muscle cell death is a significant contributor to the severe neuromuscular pathology seen in the Lama2-null mouse model of MDC1A. To extend our understanding of pathogenesis due to laminin-{alpha}2-deficiency, we have now analyzed molecular mechanisms of Bax regulation in normal and laminin-{alpha}2-deficient muscles and cells, including myogenic cells obtained from patients with a clinical diagnosis of MDC1A. In mouse myogenic cells, we found that, as in non-muscle cells, Bax co-immunoprecipitated with the multifunctional protein Ku70. In addition, cell permeable pentapeptides designed from Ku70, termed Bax-inhibiting peptides (BIPs), inhibited staurosporine-induced Bax translocation and cell death in mouse myogenic cells. We also found that acetylation of Ku70, which can inhibit binding to Bax and can be an indicator of increased susceptibility to cell death, was more abundant in Lama2-null than in normal mouse muscles. Furthermore, myotubes formed in culture from human laminin-{alpha}2-deficient patient myoblasts produced high levels of activated caspase-3 when grown on poly-L-lysine, but not when grown on a laminin-{alpha}2-containing substrate or when treated with BIPs. Finally, cytoplasmic Ku70 in human laminin-{alpha}2-deficient myotubes was both reduced in amount and more highly acetylated than in normal myotubes. Increased susceptibility to cell death thus appears to be an intrinsic property of human laminin-{alpha}2-deficient myotubes. These results identify Ku70 as a regulator of Bax-mediated pathogenesis and a therapeutic target in laminin-{alpha}2-deficiency.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.